MUC1 and idiopathic pulmonary fibrosis: Response to pirfenidone therapy correlates with changes in serum KL-6 over time in one study [101] Bergantini et al. evaluated serial measurements of serum KL-6 in IPF patients treated with nintedanib, and demonstrated an indirect correlation with forced vital capacity (FVC) percentages and KL-6 values.